Question 1

What is Immunitas Therapeutics?

Accepted Answer

Immunitas Therapeutics is a Entity.

Question 2

How often does Immunitas Therapeutics appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Immunitas Therapeutics first tracked by Ergen?

Accepted Answer

First tracked on May 12, 2026.

Question 4

When was Immunitas Therapeutics last mentioned in news?

Accepted Answer

Last active on May 13, 2026.

Question 5

What is Immunitas Therapeutics's current news sentiment?

Accepted Answer

Aggregate sentiment score: 80 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Immunitas Therapeutics in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Immunitas Therapeutics?

Accepted Answer

Boehringer Ingelheim licenses Immunitas antibody program (May 12, 2026, 6 articles).

Question 8

How did the "Boehringer Ingelheim licenses Immunitas antibody program" event impact Immunitas Therapeutics?

Accepted Answer

Immunitas Therapeutics licensed its preclinical antibody program to Boehringer Ingelheim, receiving an upfront payment and eligibility for milestone payments up to €407.5 million, plus royalties, which will help advance its novel therapeutic into clinical development.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.